EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen

EVOQ Therapeutics公司宣布与安进公司达成许可和合作协议

2021-01-13 23:33:00 BioSpace

本文共539个字,阅读需2分钟

EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. Under the terms of the agreement, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization. In exchange for exclusive rights to selected autoimmune programs, Amgen will make upfront and milestone payments potentially totaling more than $240 million, as well as pay royalties on sales of resulting therapies. Amgen is a world leader in the treatment of autoimmune disorders, with a portfolio that includes both innovative medicines, including Otezla® and Enbrel®, and biosimilar products, such as AMGEVITA® and AVSOLA® . About EVOQ Therapeutics EVOQ Therapeutics is a biopharmaceutical company focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQ's technology platform utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens for recognition by the immune system. www.evoqtherapeutics.com View original content:http://www.prnewswire.com/news-releases/evoq-therapeutics-announces-a-license-and-collaboration-agreement-with-amgen-301207118.html SOURCE EVOQ Therapeutics
EVOQ Therapeutics公司今天宣布与安进公司就发现和开发治疗自身免疫疾病的新药物达成许可和合作协议。根据协议条款,安进和EVOQ将在临床前开发方面进行合作,安进将负责临床开发和商业化。作为对选定的自身免疫项目的独家权利的交换,安进公司将支付总额可能超过2.4亿美元的预付款和里程碑付款,以及对由此产生的疗法的销售支付版税。安进公司是治疗自身免疫疾病的全球领先企业,其产品组合既包括Otezla®和Enbrel®等创新药物,也包括Amgevita®和Avsola®等生物类似产品。 关于EVOQ Therapeutics EVOQ Therapeutics是一家生物制药公司,专注于发现和开发治疗自身免疫性疾病患者的药物。EVOQ的技术平台采用了一种专有的合成高密度脂蛋白纳米盘,该盘已被优化以传递抗原,供免疫系统识别。www.evoqtherapeutics.com 查看原始内容:http://www.prnewswire.com/news-releases/evoq-therapeutics-announces-a-license-and-collaboration-agreement-with-amgen-301207118.html 源EVOQ治疗学

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文